Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-04 4:24 pm Sale |
2025-03-31 | 13G | Haemonetics Corporation HAE |
Capital Research Global Investors | 1,577,323 3.100% |
-2,865,330 (-64.50%) |
Filing History |
| 2024-11-14 1:28 pm Purchase |
2024-09-30 | 13G | Haemonetics Corporation HAE |
T. Rowe Price Investment Management, Inc. | 2,850,637 5.600% |
2,850,637 (New Position) |
Filing History |
| 2024-11-12 12:54 pm Sale |
2024-11-07 | 13G | Haemonetics Corporation HAE |
Capital Research Global Investors | 4,442,653 8.700% |
-2,080,915 (-31.90%) |
Filing History |
| 2024-11-08 10:41 am Purchase |
2024-09-30 | 13G | Haemonetics Corporation HAE |
WELLINGTON MANAGEMENT CO LLP | 4,230,850 8.270% |
962,767 (+29.46%) |
Filing History |
| 2024-02-13 5:06 pm Purchase |
2023-12-29 | 13G | Haemonetics Corporation HAE |
The Vanguard Group | 5,406,309 10.650% |
163,473 (+3.12%) |
Filing History |
| 2024-02-13 3:28 pm Sale |
2023-12-31 | 13G | Haemonetics Corporation HAE |
Neuberger Berman Group LLC | 3,531,181 6.960% |
-342,255 (-8.84%) |
Filing History |
| 2024-02-09 5:49 pm Purchase |
2024-02-07 | 13G | Haemonetics Corporation HAE |
Capital Research Global Investors | 6,523,568 12.900% |
567,504 (+9.53%) |
Filing History |
| 2024-02-08 10:21 am Sale |
2023-12-29 | 13G | Haemonetics Corporation HAE |
WELLINGTON MANAGEMENT CO LLP | 3,268,083 6.440% |
-766,670 (-19.00%) |
Filing History |
| 2024-01-23 4:13 pm Purchase |
2023-12-31 | 13G | Haemonetics Corporation HAE |
BLACKROCK INC BLK |
6,056,881 11.900% |
158,261 (+2.68%) |
Filing History |
| 2023-02-13 3:32 pm Purchase |
2023-02-14 | 13G | Haemonetics Corporation HAE |
Capital Research Global Investors | 5,956,064 11.800% |
504,058 (+9.25%) |
Filing History |
| 2023-02-10 2:10 pm Sale |
2022-12-31 | 13G | Haemonetics Corporation HAE |
Neuberger Berman Group LLC | 3,873,436 7.650% |
-3,085 (-0.08%) |
Filing History |
| 2023-02-09 11:22 am Purchase |
2022-12-30 | 13G | Haemonetics Corporation HAE |
The Vanguard Group | 5,242,836 10.360% |
47,641 (+0.92%) |
Filing History |
| 2023-02-06 3:00 pm Sale |
2022-12-30 | 13G | Haemonetics Corporation HAE |
WELLINGTON MANAGEMENT CO LLP | 4,034,753 7.970% |
-1,502,785 (-27.14%) |
Filing History |
| 2023-01-26 08:52 am Unchanged |
2022-12-31 | 13G | Haemonetics Corporation HAE |
BLACKROCK INC BLK |
5,898,620 11.700% |
0 (Unchanged) |
Filing History |
| 2023-01-20 3:00 pm Sale |
2022-12-31 | 13G | Haemonetics Corporation HAE |
BLACKROCK INC BLK |
5,898,620 11.700% |
-793,726 (-11.86%) |
Filing History |
| 2022-10-11 10:07 am Purchase |
2022-09-30 | 13G | Haemonetics Corporation HAE |
The Vanguard Group | 5,195,195 10.120% |
314,259 (+6.44%) |
Filing History |
| 2022-04-08 11:19 am Purchase |
2022-04-11 | 13G | Haemonetics Corporation HAE |
Capital Research Global Investors | 5,452,006 10.700% |
3,402,873 (+166.06%) |
Filing History |
| 2022-02-14 2:29 pm Purchase |
2021-12-31 | 13G | Haemonetics Corporation HAE |
Neuberger Berman Group LLC | 3,876,521 7.590% |
1,043,472 (+36.83%) |
Filing History |
| 2022-02-11 12:22 pm Sale |
2022-02-14 | 13G | Haemonetics Corporation HAE |
Capital Research Global Investors | 2,049,133 4.000% |
-726,503 (-26.17%) |
Filing History |
| 2022-02-10 08:16 am Purchase |
2021-12-31 | 13G | Haemonetics Corporation HAE |
The Vanguard Group | 4,880,936 9.550% |
28,654 (+0.59%) |
Filing History |